Journal
JOURNAL OF BIOMEDICAL RESEARCH
Volume 32, Issue 5, Pages 317-326Publisher
NANJING MEDICAL UNIV
DOI: 10.7555/JBR.31.20160168
Keywords
checkpoint inhibitor; CTLA-4; PD-1; immunotherapy; cancer
Categories
Funding
- MRC DPFS grant [MR/M015696/1]
- Ministry of Sciences and Technology of China [2013DFG32080]
- MRC [MR/M015696/1] Funding Source: UKRI
Ask authors/readers for more resources
In recent years immune checkpoint inhibitors have garnered attention as being one of the most promising types of immunotherapy on the horizon. There has been particular focus on the immune checkpoint molecules, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) which have been shown to have potent immunomodulatory effects through their function as negative regulators of T cell activation. CTLA-4, through engagement with its ligands B7-1 (CD80) and B7-2 (CD86), plays a pivotal role in attenuating the activation of naive and memory T cells. In contrast, PD-1 is primarily involved in modulating T cell activity in peripheral tissues via its interaction with PD-L1 and PD-L2. The discovery of these negative regulators of the immune response was crucial in the development of checkpoint inhibitors. This shifted the focus from developing therapies that targeted activation of the host immune system against cancer to checkpoint inhibitors, which aimed to mediate tumor cell destruction through the removal of coinhibitory signals blocking anti-tumor T cell responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available